CONFIDENTIAL
04 · 2026
Dercum’s Disease action plan
A personalized synthesis of records, biomarkers, imaging, and literature for a post-menopausal Type II (generalized nodular) Dercum's case dominated by pain, inflammation, and lymphatic dysfunction.
- Prepared for
- Sample · P.C., 52
- Condition
- Dercum's Disease, Type II
- Pages
- 33
- Lead reviewers
- Giannini · Paramonov
- 01Executive summary
- 02Case synthesis
- 03Disease model — your version
- 04Specialist pathway
- 05Clinical workup and imaging
- 06Signal analysis — your activation map
- 07Genetic findings — variant-level review
- 08DEXA body composition
- 09Intervention prioritization — Ternary Method applied
- 10Medical therapy — discussion points
- 11Supplement framework
- 12Lymphatic drainage, PT, and movement
- 13Diet, sleep, and recovery
- 14Monitoring plan
- 1590-day execution blueprint
- 16Questions for your physicians
- 17Resources and communities
Executive summary
What this plan says and the three moves that matter most in the next 30 days.
A 52-year-old post-menopausal woman with an 8-year history of progressively worsening painful subcutaneous nodules, diagnosed with Dercum’s Disease (Type II, generalized nodular) in December 2024 after six years cycling through fibromyalgia, polymyalgia rheumatica, and obesity-related pain diagnoses.
- 01
- Initiate a formal pain-phenotype workup within 30 days. Dercum’s pain is neither purely neuropathic, nor purely inflammatory, nor purely lymphatic — and the proportions matter for treatment selection. Quantitative sensory testing (QST), pain phenotyping (DN4 / S-LANSS), and skin biopsy for small-fiber neuropathy should precede any medication changes.
- 02
- Structured tramadol taper followed by low-dose naltrexone (LDN) trial. Your CYP2D6 *1/*4 intermediate metabolizer status plus OPRM1 A118G heterozygous means tramadol has never been efficient analgesia for you. LDN 1.5–4.5 mg nightly has the strongest growing evidence base in Dercum’s among off-label oral agents.
- 03
- Certified lymphedema evaluation + compression program. Bilateral dependent edema with a positive Stemmer sign on the right is clinical-stage lymphedema that has never been formally evaluated. Manual lymphatic drainage plus graduated compression is the single most modifiable lever outside of pharmacologic pain management.
- 04
- Parallel workup for the MGUS + ANA finding. Trace IgM-kappa with ANA 1:160 speckled warrants hematology and rheumatology consultation — not alarming in isolation, not benign either, and it should not gate the main plan.
Case synthesis
Timeline, clinical picture, and stated goals reconstructed into one coherent narrative.
Clinical timeline
| Year | Event |
|---|---|
| 2018 | First noticed painful subcutaneous nodules in inner thighs and upper arms. Initial PCP assessment: 'lipomas, nothing to worry about.' |
| 2019 | Pain progression. Diagnosed with fibromyalgia. Duloxetine started. |
| 2021 | Menopause (final period Feb 2021). Symptom acceleration. |
| 2022 | Polymyalgia rheumatica presumed; 3-month prednisone taper with no benefit. PT intake. |
| 2023 | Tramadol 50 mg TID added. Medical cannabis trial — modest benefit, stopped for work reasons. |
| Dec 2024 | Rheumatology consultation with skin biopsy confirms Dercum's Disease (Type II, generalized nodular). ~6-year diagnostic delay. |
| 2025 – present | Function remains limited. Career reduced to part-time. Opioid dependence unresolved. |
Stated goals (kickoff call, Feb 14, 2026)
- “I want pain relief that doesn’t require opioids.”
- “I want to understand what’s actually driving this, not just manage it.”
- “I want to work full-time again if possible, or make peace with not working full-time.”
- “I want a plan I can actually follow on the days when I can barely move.”
- “I want to know what’s realistic to expect at year five, year ten.”
Current medications
Duloxetine 60 mg daily (~3 years), tramadol 50 mg TID (~18 months), atorvastatin 20 mg daily, lisinopril 10 mg daily, vitamin D3 2,000 IU daily, calcium carbonate 600 mg BID. Prior therapy trials (all ceased): gabapentin (cognitive side effects), amitriptyline (weight gain), prednisone for presumed PMR (no benefit), acupuncture (no benefit).
Disease model — your version
Four upstream drivers feed one downstream pain phenotype. Three of four are modifiable.
Unlike Madelung's Disease, you do not have a dominant removable driver like alcohol. Instead, you have a set of medium-leverage drivers that must be addressed in parallel. This is why the 90-day plan runs six workstreams simultaneously rather than sequentially — no single intervention is likely to be transformative, but the combination can be.
What that means practically
- Inflammation and lymphatic load are causally linked. Lymphatic load feeds tissue inflammation; tissue inflammation amplifies nociceptor sensitization; nociceptor sensitization drives the pain phenotype. Addressing one lowers the others.
- Low-dose naltrexone sits at the centerpiece because it crosses all three pathways — immunomodulatory, anti-inflammatory, and analgesic via non-opioid mechanisms.
- The MGUS + ANA finding is a parallel track, not a gate. Hematology and rheumatology workup in month 2 while the main plan proceeds.
See this depth applied to your condition.
This is a sample built on a composite case — we don’t publish the full sample. A Ternary Brief on your own situation is free and takes about three minutes.
You’re reading 3 of 17 sections. The full Precision Deep Dive continues with specialist pathway, clinical workup and imaging, signal analysis, genetic findings, and more.
Educational sample on a composite case. Your brief and any report are built from your own situation and are never shared.